1. Participants who have been confirmed to have a history of SARS-CoV-2 infection.2. A loss of &gt, 200 mL of whole blood or blood components within 12 weeks or &gt, 100 mL within 4 weeks of the first dose of study intervention in male participants. A loss of &gt, 200 mL of whole blood or blood components within 16 weeks or &gt, 100 mL within 4 weeks of the first dose of study intervention in female participants.3. Current enrollment or past participation within the last 30 days before signing of ICF in any other clinical study involving an clinical study or any other type of medical research.4. Participants who have been confirmed to be positive in human immunodeficiency virus (HIV) antigen/antibody test, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody test result.

1. Participants who have been confirmed to have a history of SARS-CoV-2 infection.2. A loss of &gt, 200 mL of whole blood or blood components within 12 weeks or &gt, 100 mL within 4 weeks of the first dose of study intervention in male participants. A loss of &gt, 200 mL of whole blood or blood components within 16 weeks or &gt, 100 mL within 4 weeks of the first dose of study intervention in female participants.3. Current enrollment or past participation within the last 30 days before signing of ICF in any other clinical study involving an clinical study or any other type of medical research.4. Participants who have been confirmed to be positive in human immunodeficiency virus (HIV) antigen/antibody test, hepatitis B surface antigen (HBsAg), and hepatitis C virus (HCV) antibody test result.